Xintela AB 2025 AR2
The report highlights Xintela's clinical and operational progress in 2025, particularly the successful completion of its Phase I/IIa clinical study of XSTEM for knee osteoarthritis, which demonstrated disease-modifying potential and long-lasting pain reduction. The company also completed its clinical study on difficult-to-heal venous leg ulcers and expanded its veterinary medicine collaborations through an agreement with EQGen Biomedical. Additionally, Xintela's oncology subsidiary, Targinta, initiated a collaboration with Memorial Sloan Kettering Cancer Center to develop antibody-based therapies for aggressive sarcoma. Financially, Xintela secured funding through a rights issue, warrants, and loans to support its ongoing development projects and GMP facility operations.
Company: Xintela AB
Sector: Health Care
Country: Sweden
Year: 2025
Type: AR2
Pages: 41
Xintela AB
Annual Report
The report highlights Xintela's clinical and operational progress in 2025, particularly the successful completion of its Phase I/IIa clinical study of XSTEM for knee osteoarthritis, which demonstrated disease-modifying potential and long-lasting pain reduction. The company also completed its clinical study on difficult-to-heal venous leg ulcers and expanded its veterinary medicine collaborations through an agreement with EQGen Biomedical. Additionally, Xintela's oncology subsidiary, Targinta, initiated a collaboration with Memorial Sloan Kettering Cancer Center to develop antibody-based therapies for aggressive sarcoma. Financially, Xintela secured funding through a rights issue, warrants, and loans to support its ongoing development projects and GMP facility operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees